losartan and warfarin

losartan has been researched along with warfarin in 20 studies

Research

Studies (20)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (5.00)	18.2507
2000's	4 (20.00)	29.6817
2010's	14 (70.00)	24.3611
2020's	1 (5.00)	2.80

Authors

Authors	Studies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Avdeef, A; Tam, KY	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Bjornsson, TD; Deutsch, PJ; Goldberg, MR; Kong, AN; Osborne, B; Tomasko, L; Waldman, SA	1
Kamal, Z; Molden, E; Nordstad, MG	1
Bergman, U; Bertilsson, L; Engström Hellgren, K; Helldén, A; Masquelier, M; Nilsson Remahl, I; Odar-Cederlöf, I; Ramsjö, M	1
Gorski, JC; Lindamood, C; Ortiz, S; Rackley, R; Shaw, A	1
Bertilsson, L; Eliasson, E; Masquelier, M; Ostervall, J; Otto, S; Rosenborg, S; Stenberg, M; Yue, QY	1
Chong, E; Kalia, V; Willsie, S; Winkle, P	1
Arslanbekova, SM; Golukhova, EZ; Kazakov, RE; Kuznetsova, EV; Smirnov, VV; Sychev, DA	1
Li, M; Shao, J; Wu, J; Wu, P	1
Cai, JP; Chen, H; Chong, J; Dai, DP; Geng, PW; Liu, J; Lü, Y; Wang, SH; Wu, HL; Yang, JF; Zhou, Q; Zhou, S	1

Reviews

1 review(s) available for losartan and warfarin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

3 trial(s) available for losartan and warfarin

Article	Year
Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. Journal of clinical pharmacology, 1995, Volume: 35, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Angiotensin Receptor Antagonists; Anticoagulants; Antihypertensive Agents; Biphenyl Compounds; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Humans; Imidazoles; Losartan; Male; Prothrombin Time; Receptors, Angiotensin; Stereoisomerism; Tetrazoles; Warfarin	1995
Clinically significant CYP2C inhibition by noscapine but not by glucosamine. Clinical pharmacology and therapeutics, 2010, Volume: 88, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anticoagulants; Antitussive Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Drug Interactions; Female; Glucosamine; Humans; Losartan; Male; Middle Aged; Noscapine; Omeprazole; Phenotype; Warfarin; Young Adult	2010
Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects. Journal of nephrology, 2014, Volume: 27, Issue:6 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anticoagulants; Area Under Curve; Cardiotonic Agents; Chelating Agents; Digoxin; Diuretics; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Ferric Compounds; Furosemide; Half-Life; Healthy Volunteers; Humans; Losartan; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Statistical; Omeprazole; Proton Pump Inhibitors; Risk Assessment; Sucrose; Warfarin; Young Adult	2014

Other Studies

16 other study(ies) available for losartan and warfarin

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability? Journal of medicinal chemistry, 2010, May-13, Volume: 53, Issue:9 Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
[A 60-year-old man with heart failure, dry cough and elevated INR values]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2008, Aug-14, Volume: 128, Issue:15 Topics: Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Coronary Thrombosis; Cough; Cytochrome P-450 CYP2C9; Genotype; Heart Failure; Humans; International Normalized Ratio; Losartan; Male; Middle Aged; Pharmacogenetics; Polypharmacy; Ramipril; Warfarin	2008
Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. European journal of clinical pharmacology, 2010, Volume: 66, Issue:8 Topics: Alleles; Angiotensin II Type 1 Receptor Blockers; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Ataxia; Behcet Syndrome; Case-Control Studies; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Fatigue; Female; Fluconazole; Humans; Losartan; Middle Aged; Pharmaceutical Preparations; Phenotype; Phenytoin; Polymorphism, Genetic; Speech Intelligibility; Warfarin	2010
Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. Journal of clinical pharmacology, 2011, Volume: 51, Issue:4 Topics: Adult; Antihypertensive Agents; Benzopyrans; Cytochrome P-450 CYP2D6; Digoxin; Drug Interactions; Ethanolamines; Female; Fluoxetine; Furosemide; Genotype; Humans; Hydrochlorothiazide; Losartan; Male; Middle Aged; Nebivolol; Ramipril; Warfarin; Young Adult	2011
[Relationship between warfarin dosing and activity of CYP2C9 assessed by the content of losartan and its metabolite E-3174 in the urine of patients with mechanical prosthetic heart valves]. Kardiologiia, 2013, Volume: 53, Issue:12 Topics: Adult; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Biotransformation; Cardiovascular Agents; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Drug Monitoring; Female; Genotype; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Imidazoles; Losartan; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Postoperative Period; Tetrazoles; Warfarin	2013
[Mechanism of losartan suppressing vascular calcification in rat aortic artery]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2016, Volume: 32, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Arteries; Blotting, Western; Bone Morphogenetic Protein 2; Core Binding Factor Alpha 1 Subunit; Gene Expression; Immunohistochemistry; Losartan; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Random Allocation; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Vascular Calcification; Vitamin K 1; Warfarin	2016
An identification and functional evaluation of a novel CYP2C9 variant CYP2C962. Chemico-biological interactions, 2020, Aug-25, Volume: 327* Topics: Aged, 80 and over; Alleles; Animals; Cytochrome P-450 CYP2C9; Diclofenac; Enzyme Assays; Humans; Kinetics; Losartan; Male; Microsomes; Point Mutation; Polymorphism, Genetic; Recombinant Proteins; Spodoptera; Tolbutamide; Vitamin K Epoxide Reductases; Warfarin	2020